Clinical trial
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent…
NCT00002939 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00002939 |
|---|---|
| Title | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer |
| Official title | A Phase I Trial of Dose Escalated Irinotecan (CPT-11) With Paclitaxel in Patients With Metastatic or Recurrent Malignancies |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, paclitaxel |
| Enrollment | 21 |
| Start date | Nov 1, 1996 |
| Primary completion | Feb 1, 2001 |
| Completion | Apr 1, 2002 |
| First posted | Apr 29, 2004 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: